Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Vor Bio (Nasdaq: VOR) will host a live webcast to present newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease.
The study was conducted by collaborator RemeGen. Vor Bio management and Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results.
Webcast: Tuesday, October 28, 2025 at 4:30 PM Eastern Time. Registration options include listen-only and listen-with-live Q&A links; a replay will be posted at https://ir.vorbio.com/events-presentations/ approximately two hours after the call and will remain available for 30 days.
Vor Bio (Nasdaq: VOR) ospiterà una presentazione webcast in diretta per presentare i dati clinici recentemente divulgati e di ultima ora 48-settimane di Fase 3 in Cina per telitacicept nella malattia di Sjögren primaria.
Lo studio è stato condotto dal collaboratore RemeGen. La direzione di Vor Bio e Ronald van Vollenhoven, M.D., Ph.D., Professore di Reumatologia presso l'Amsterdam University Medical Center, rivedranno i principali risultati di efficacia e sicurezza.
Webcast: martedì 28 ottobre 2025 alle 16:30 Ora Orientale. Le opzioni di registrazione includono link di ascolto in sola ascolto e ascolto con Q&A in diretta; una replica sarà pubblicata su https://ir.vorbio.com/events-presentations/ circa due ore dopo la chiamata e resterà disponibile per 30 giorni.
Vor Bio (Nasdaq: VOR) organizará una transmisión web en vivo para presentar datos clínicos recientemente divulgados y de última hora de 48 semanas de Fase 3 en China para telitacicept en la enfermedad de Sjögren primaria.
El estudio fue realizado por el colaborador RemeGen. La dirección de Vor Bio y Ronald van Vollenhoven, M.D., Ph.D., Profesor de Reumatología en el Amsterdam University Medical Center, revisarán los principales resultados de eficacia y seguridad.
Webcast: martes, 28 de octubre de 2025 a las 16:30 hora del Este. Las opciones de registro incluyen enlaces de escucha solamente y de escucha con preguntas y respuestas en vivo; una repetición se publicará en https://ir.vorbio.com/events-presentations/ aproximadamente dos horas después de la llamada y estará disponible durante 30 días.
Vor Bio (Nasdaq: VOR)는 중국에서 48주 단계 3 임상 데이터의 새로 공개된 정보를 telitacicept에 대해 생방송으로 발표하기 위해 라이브 웹캐스트를 개최합니다.
연구는 협력사 RemeGen이 수행했습니다. Vor Bio 경영진과 암스테르담대학교 의과대학의 류마티스학 교수인 Ronald van Vollenhoven 박사도 주요 유효성 및 안전성 결과를 검토할 예정입니다.
웹캐스트: 2025년 10월 28일 화요일 오후 4:30(동부 표준시). 등록 옵션에는 단독 청취 링크 및 라이브 Q&A가 포함되며, 통화 약 2시간 후에 https://ir.vorbio.com/events-presentations/에서 재방송이 게시되며 30일간 이용 가능합니다.
Vor Bio (Nasdaq: VOR) organisera une web diffusion en direct pour présenter des données cliniques récentes et très récentes de 48 semaines de Phase 3 en Chine pour telitacicept dans la maladie de Sjögren primaire.
L’étude a été réalisée par le partenaire RemeGen. La direction de Vor Bio et Ronald van Vollenhoven, M.D., Ph.D., Professeur de Rhumatologie à l’Amsterdam University Medical Center, passeront en revue les principaux résultats d’efficacité et de sécurité.
Webcast : mardi 28 octobre 2025 à 16:30 heure de l’Est. Les options d’inscription incluent des liens d’écoute en mode écoute seule et écoute avec questions/réponses en direct ; une rediffusion sera publiée sur https://ir.vorbio.com/events-presentations/ environ deux heures après l’appel et restera disponible pendant 30 jours.
Vor Bio (Nasdaq: VOR) wird einen Live-Webcast veranstalten, um neu bekannt gegebene, aktuelle 48-Wochen Phase-3 klinische Daten in China für telitacicept bei der primären Sjögren-Krankheit vorzustellen.
Die Studie wurde von dem Kooperationspartner RemeGen durchgeführt. Das Vor Bio-Management und Ronald van Vollenhoven, M.D., Ph.D., Professor für Rheumatologie am Amsterdam University Medical Center, werden zentrale Wirksamkeits- und Sicherheitsresultate überprüfen.
Webcast: Dienstag, 28. Oktober 2025 um 16:30 Uhr Eastern Time. Registrierungsoptionen umfassen Listen-Only- und Listen-with-Live-Q&A-Links; eine Aufzeichnung wird ca. zwei Stunden nach dem Anruf unter https://ir.vorbio.com/events-presentations/ veröffentlicht und für 30 Tage verfügbar bleiben.
Vor Bio (Nasdaq: VOR) ستستضيف بثًا مباشرًا عبر الويب لعرض بيانات سريرية حديثة وكاشفة من 48 أسبوعاً من المرحلة 3 في الصين لـ telitacicept في مرض جفاف العين الأولي (جفاف العين Sjögren).
أُجريَت الدراسة من قِبل المتعاون RemeGen. ستستعرض إدارة Vor Bio و Ronald van Vollenhoven، د.م، دكتور، أستاذ أمراض الروماتيزم في مركز أمستردام الطبي الجامعي، النتائج الأساسية للفعالية والسلامة.
البث المباشر: الثلاثاء، 28 أكتوبر 2025 الساعة 4:30 مساءً بتوقيت الساحل الشرقي. تتضمن خيارات التسجيل روابط للاستماع فقط والاستماع مع أسئلة وأجوبة مباشرة؛ ستُنشَر إعادة بث على https://ir.vorbio.com/events-presentations/ بعد المكالمة بحوالي ساعتيْن وستظل متاحة لمدة 30 يومًا.
Vor Bio (纳斯达克代码: VOR) 将举行一次现场直播网络广播，介绍在中国针对原发性干燥综合征的 telitacicept 的最新披露、最新的 48 周 Phase 3 临床数据。
本研究由合作者 RemeGen 进行。Vor Bio 管理层与 Ronald van Vollenhoven 医学博士、博士、阿姆斯特丹大学医学中心风湿科教授将回顾关键的有效性和安全性结果。
网络广播： 2025 年 10 月 28 日，星期二，东部时间下午 4:30。注册选项包括仅监听和带现场问答的监听链接；通话约两小时后将在 https://ir.vorbio.com/events-presentations/ 发布回放，并将保持可用 30 天。
- None.
- None.
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it will host a live webcast to present and discuss the newly disclosed, late-breaking 48-week Phase 3 clinical data in China for telitacicept in primary Sjögren’s disease. The study was conducted by Vor Bio’s collaborator RemeGen Co., Ltd (HKEX: 9995, SHA: 688331).
During the webcast, Vor Bio management, joined by Ronald van Vollenhoven, M.D., Ph.D., Professor of Rheumatology at Amsterdam University Medical Center, will review key efficacy and safety results from the trial.
Webcast Details:
Date: Tuesday, October 28, 2025
Time: 4:30 PM Eastern Time
Access:
- Listen Only: Listeners can register for the webcast via this LINK
- Listen and Live Q&A: Analysts or investors wishing to participate in the Q&A session should use this LINK
Replay: A replay of the webcast will be available via the investor section of the Company’s website at https://ir.vorbio.com/events-presentations/ approximately two hours after the call’s conclusion and will remain available for a period of 30 days.
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
When will Vor Bio (VOR) present the China Phase 3 telitacicept data?
What data will Vor Bio discuss during the October 28, 2025 VOR webcast?
Who will join Vor Bio's webcast to discuss the telitacicept Phase 3 results?
How can investors register to listen or ask questions during the VOR webcast?
Will Vor Bio post a replay of the October 28, 2025 webcast for VOR investors?
Which company conducted the China Phase 3 telitacicept study discussed by Vor Bio (VOR)?
